Fruquintinib inhibited the VEGF/VEGFR pathway in in vitro assays (32) and in animal models of colon cancer where it showed less toxicity than its predecessors while suppressed angiogenesis and tumorigenesis in combination with doxorubicin and oxaliplatin (33) or anti-PD-1-based immunotherapy. This evidence concerns the gene KDR and colonic neoplasm.